Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation

Remdesivir and Dexamethasone represent the cornerstone of therapy for critically ill patients with acute hypoxemic respiratory failure caused by Coronavirus Disease 2019 (COVID-19). However, clinical efficacy and safety of concomitant administration of Remdesivir and Dexamethasone (Rem-Dexa) in seve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2022-04, Vol.17 (4), p.e0267038-e0267038
Hauptverfasser:	De Pascale, Gennaro, Cutuli, Salvatore Lucio, Carelli, Simone, Xhemalaj, Rikardo, Rosà, Tommaso, Bello, Giuseppe, Vargas, Joel, Cesarano, Melania, Montini, Luca, Tanzarella, Eloisa Sofia, Pintaudi, Gabriele, Di Muro, Mariangela, Grieco, Domenico Luca, Antonelli, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Adenosine Monophosphate - analogs & derivatives Alanine - analogs & derivatives Antiviral drugs Biology and Life Sciences Clinical outcomes Cohort analysis Cohort Studies Complications Complications and side effects Coronaviruses COVID-19 COVID-19 - drug therapy Critical Illness Dexamethasone Dexamethasone - therapeutic use Dual energy X-ray absorptiometry Health services High flow Hospitals Humans Intensive care units Intubation Kidneys Laboratories Mechanical ventilation Medicine and Health Sciences Mortality Noninvasive Ventilation Nosocomial infections Ostomy Oxygen Oxygen therapy Patient outcomes Patients Physical Sciences Pneumonia Prospective Studies Regression analysis Regression models Respiratory failure RNA polymerase Sepsis Severe acute respiratory syndrome coronavirus 2 Steroids Tertiary Therapy Urinary tract infections Ventilation Ventilators Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!